Danaher (NYSE:DHR) is built through acquisitions, but it's an odd company in that it doesn't necessarily (or even often) buy great companies. Instead, Danaher seems to focus on buying companies that can be made substantially better under its aegis. With that profile in mind, Danaher's acquisition of IRIS International (Nasdaq:IRIS) makes a great deal of sense.

Discount Brokers Comparison: Your one-stop shop for finding the perfect broker for your investments.

The Deal Danaher Proposes
Danaher announced Monday that it had reached an agreement with small-cap diagnostics company IRIS to acquire the company in a tender offer. Danaher will be paying $19.50 per share, for a total consideration of about $338 million. At that price, Danaher is giving IRIS shareholders about a 45% premium to Friday's close and the highest price they've seen in roughly five years. At this price, Danaher is paying about 2.4 to 2.6 times 2012/2013 revenue. While that is a relatively low multiple for med-tech, IRIS has struggled of late with its margins and is consequently not as profitable as most med-tech companies.

SEE: Biggest Merger and Acquisition Disasters

What Danaher Is Getting
In buying IRIS, Danaher is buying a company that has long seemed to have good technology, but where the management execution and market valuation have not kept pace. IRIS is a leader in automated urine microscopy, a market that should be increasingly valuable as hospitals find themselves squeezed between increasing lab volume and a tight lab-tech labor market. Despite having a technological edge on Japan's Sysmex, IRIS's small size has limited its ability to really gain share and momentum in a market that is still under-penetrated with automated solutions.

While most of the $600 million urinalysis market is dominated with chemistry systems from companies like Roche (OTC:RHHBY) and Siemens (NYSE:SI), roughly half of clinical reference and hospital labs use manual microscopy for urinalysis. That leaves a roughly $250 million addressable market for automated microscopy systems - a market that was growing more than 20% before the major cap-ex slowdown in healthcare.

What is especially attractive about this market is that once a system is installed, it creates a stream of captive revenue to the company for high-margin consumables. This ought to be especially appealing to Danaher - integrating IRIS should create the potential for better placements (through a larger, better-funded sales force) and better margins for the consumables.

This is not all that IRIS offers. The company has also been working to build its sample processing and molecular diagnostics business. In particular, IRIS has been working for years to develop and market its NADiA ProsVue test - a highly sensitive prostate cancer test. While PSA testing has started to fall out of favor with some clinicians, there are still reasons to believe that this could be a high-value test for monitoring prostactecomy patients for recurrence.

Definitely Some Work to Do
There are definitely some valid reasons why Danaher is not having to pay upwards of three times revenue to get IRIS. While I am not aware of much debate regarding the quality of IRIS's technology, IRIS frustrated many analysts and investors with delays in getting the Velocity and iRicell products on the market. Likewise, there have been frustrations regarding manufacturing leverage and overall margin improvements, to say nothing of questions as to whether the company can develop and monetize promising technology for the hematology market.

Now the question will be the extent to which better sales and marketing support and improved manufacturing efficiencies can improve the returns from this business. I still do believe that automated urine microscopy is under-penetrated in the U.S., and I also believe that Danaher has done a solid job of improving its Beckman Coulter diagnostics business - another business that was in need of improvement at the time Danaher bought it.

The Bottom Line
I used to follow IRIS International back in my sell-side analyst days, and although the stock did not perform especially well for me, or my clients, I'm glad to see that management is getting a solid buyout offer. The company has had its challenges, but I think Danaher is buying in at an opportune time and I think it can do good things with IRIS's technology and products.

For Danaher, there is some risk to this deal, but I think simple execution ought to fuel solid returns on this deal. Given that execution is one of the things Danaher does well, that ought to de-risk this deal for shareholders. IRIS is not very likely to be a huge factor in the value of Danaher in 2013 or 2018, but this strikes me as the sort of incrementally value-additive deal that has long helped build shareholder value at Danaher.

Disclosure: Author has owned shares of Roche since 2011.

Related Articles
  1. Investing News

    Latest Labor Numbers: Good News for the Market?

    Some economic numbers are indicating that the labor market is outperforming the stock market. Should investors be bullish?
  2. Investing News

    Stocks with Big Dividend Yields: 'It's a Trap!'

    Should you seek high yielding-dividend stocks in the current investment environment?
  3. Investing News

    Should You Be Betting with Buffett Right Now?

    Following Warren Buffett's stock picks has historically been a good strategy. Is considering his biggest holdings in 2016 a good idea?
  4. Products and Investments

    Cash vs. Stocks: How to Decide Which is Best

    Is it better to keep your money in cash or is a down market a good time to buy stocks at a lower cost?
  5. Investing News

    Who Does Cheap Oil Benefit? See This Stock (DG)

    Cheap oil won't benefit most companies, but this retailer might buck that trend.
  6. Investing

    How to Ballast a Portfolio with Bonds

    If January and early February performance is any guide, there’s a new normal in financial markets today: Heightened volatility.
  7. Stock Analysis

    Performance Review: Emerging Markets Equities in 2015

    Find out why emerging markets struggled in 2015 and why a half-decade long trend of poor returns is proving optimistic growth investors wrong.
  8. Investing News

    Today's Sell-off: Are We in a Margin Liquidation?

    If we're in market liquidation, is it good news or bad news? That party depends on your timeframe.
  9. Investing News

    Bank Stocks: Time to Buy or Avoid? (WFC, JPM, C)

    Bank stocks have been pounded. Is this the right time to buy or should they be avoided?
  10. Stock Analysis

    Why the Bullish Are Turning Bearish

    Banks are reducing their targets for the S&P 500 for 2016. Here's why.
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center